At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 210 enrolled
Drug / intervention
Etanerceptbiological
Likely dose
Etanercept 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A MULTICENTER OPEN-LABEL STUDY OF ETANERCEPT WITHDRAWAL AND RETREATMENT IN SUBJECTS WITH NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS WHO ACHIEVED ADEQUATE 24 WEEK RESPONSE
In Brief
A Phase 4 clinical trial evaluating Etanercept for Spondylitis, Ankylosing. Completed, enrolled 210 participants across 82 sites in 14 countries.
Detailed Summary
The purpose of this study is to study the benefits and risks of etanercept withdrawal in patients who have achieved a significant clinical response.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpondylitis, Ankylosing
CountriesAustralia, Belgium, Colombia, Czechia, Finland, France, Germany, Hungary, Netherlands, Poland, Spain, Sweden, Taiwan, United States
Collaborators--
Timeline
Phase 4CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 2015
Enrollment StartSep 2015
Primary CompletionMay 2019
Study CompletionSep 2019
TodayJul 2026
First PostedJul 27, 2015
Enrollment StartSep 24, 2015
Primary CompletionMay 28, 2019
Study CompletionSep 6, 2019
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 10.9 years ago
Interventions
Etanerceptbiological
50 mg subcutaneous, once weekly, 24 weeks